Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Kevin Steinke has maintained an Outperform rating on Cross Country Healthcare (NASDAQ:CCRN) but lowered the price target from $35 to $29.
August 14, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cross Country Healthcare's price target has been lowered from $35 to $29 by Barrington Research, though the Outperform rating is maintained.
The lowering of the price target by Barrington Research could potentially lead to a short-term negative sentiment among investors. However, the maintained Outperform rating indicates that the analyst still sees potential upside for the stock, which could balance out the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100